South Korea · Delayed Price · Currency is KRW Meta Biomed Statistics
Total Valuation
Meta Biomed has a market cap or net worth of KRW 105.02 billion. The enterprise value is 113.66 billion.
| Market Cap | 105.02B |
| Enterprise Value | 113.66B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | Jun 29, 2026 |
Share Statistics
Meta Biomed has 27.17 million shares outstanding. The number of shares has increased by 24.05% in one year.
| Current Share Class | 27.17M |
| Shares Outstanding | 27.17M |
| Shares Change (YoY) | +24.05% |
| Shares Change (QoQ) | +17.72% |
| Owned by Insiders (%) | 22.47% |
| Owned by Institutions (%) | 5.68% |
| Float | 21.07M |
Valuation Ratios
The trailing PE ratio is 6.53 and the forward PE ratio is 5.31.
| PE Ratio | 6.53 |
| Forward PE | 5.31 |
| PS Ratio | 1.04 |
| PB Ratio | 0.81 |
| P/TBV Ratio | 0.82 |
| P/FCF Ratio | 1,043.48 |
| P/OCF Ratio | 5.92 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.63, with an EV/FCF ratio of 1,129.31.
| EV / Earnings | 6.69 |
| EV / Sales | 1.12 |
| EV / EBITDA | 4.63 |
| EV / EBIT | 6.11 |
| EV / FCF | 1,129.31 |
Financial Position
The company has a current ratio of 1.53, with a Debt / Equity ratio of 0.35.
| Current Ratio | 1.53 |
| Quick Ratio | 1.07 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | 1.85 |
| Debt / FCF | 456.36 |
| Interest Coverage | 9.19 |
Financial Efficiency
Return on equity (ROE) is 13.67% and return on invested capital (ROIC) is 11.22%.
| Return on Equity (ROE) | 13.67% |
| Return on Assets (ROA) | 6.33% |
| Return on Invested Capital (ROIC) | 11.22% |
| Return on Capital Employed (ROCE) | 13.79% |
| Weighted Average Cost of Capital (WACC) | 6.10% |
| Revenue Per Employee | 322.25M |
| Profits Per Employee | 54.12M |
| Employee Count | 314 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 2.12 |
Taxes
In the past 12 months, Meta Biomed has paid 3.92 billion in taxes.
| Income Tax | 3.92B |
| Effective Tax Rate | 19.01% |
Stock Price Statistics
The stock price has decreased by -26.94% in the last 52 weeks. The beta is 0.53, so Meta Biomed's price volatility has been lower than the market average.
| Beta (5Y) | 0.53 |
| 52-Week Price Change | -26.94% |
| 50-Day Moving Average | 3,860.70 |
| 200-Day Moving Average | 4,407.25 |
| Relative Strength Index (RSI) | 46.69 |
| Average Volume (20 Days) | 82,691 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Meta Biomed had revenue of KRW 101.19 billion and earned 16.99 billion in profits. Earnings per share was 591.95.
| Revenue | 101.19B |
| Gross Profit | 53.18B |
| Operating Income | 18.91B |
| Pretax Income | 20.62B |
| Net Income | 16.99B |
| EBITDA | 24.85B |
| EBIT | 18.91B |
| Earnings Per Share (EPS) | 591.95 |
Balance Sheet
The company has 37.68 billion in cash and 45.93 billion in debt, with a net cash position of -8.25 billion or -303.48 per share.
| Cash & Cash Equivalents | 37.68B |
| Total Debt | 45.93B |
| Net Cash | -8.25B |
| Net Cash Per Share | -303.48 |
| Equity (Book Value) | 130.38B |
| Book Value Per Share | 4,822.20 |
| Working Capital | 30.54B |
Cash Flow
In the last 12 months, operating cash flow was 17.75 billion and capital expenditures -17.65 billion, giving a free cash flow of 100.64 million.
| Operating Cash Flow | 17.75B |
| Capital Expenditures | -17.65B |
| Depreciation & Amortization | 5.94B |
| Net Borrowing | -266.03M |
| Free Cash Flow | 100.64M |
| FCF Per Share | 3.70 |
Margins
Gross margin is 52.55%, with operating and profit margins of 18.69% and 16.79%.
| Gross Margin | 52.55% |
| Operating Margin | 18.69% |
| Pretax Margin | 20.38% |
| Profit Margin | 16.79% |
| EBITDA Margin | 24.56% |
| EBIT Margin | 18.69% |
| FCF Margin | 0.10% |
Dividends & Yields
This stock pays an annual dividend of 105.00, which amounts to a dividend yield of 2.71%.
| Dividend Per Share | 105.00 |
| Dividend Yield | 2.71% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | 16.72% |
| Buyback Yield | -24.05% |
| Shareholder Yield | -21.34% |
| Earnings Yield | 16.18% |
| FCF Yield | 0.10% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 23, 2010. It was a forward split with a ratio of 2.
| Last Split Date | Apr 23, 2010 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Meta Biomed has an Altman Z-Score of 2.94 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.94 |
| Piotroski F-Score | 5 |